

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7837797

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
PONTIFAX MEDISON FINANCE GP, L.P.	03/02/2023

**RECEIVING PARTY DATA**

<b>Name:</b>	OPIANT PHARMACEUTICALS, INC.
<b>Street Address:</b>	10710 MIDLOTHIAN TURNPIKE, SUITE 125
<b>City:</b>	NORTH CHESTERFIELD
<b>State/Country:</b>	VIRGINIA
<b>Postal Code:</b>	23235

**PROPERTY NUMBERS Total: 36**

Property Type	Number
Application Number:	62756903
PCT Number:	US2019060185
Application Number:	62776888
Application Number:	62862832
Application Number:	16704699
PCT Number:	US2019064672
Application Number:	62862830
Application Number:	16904359
PCT Number:	US2020038215
Application Number:	63037351
Application Number:	16904403
PCT Number:	US2020038211
Application Number:	62354465
Application Number:	62419736
PCT Number:	US2017039300
Application Number:	62424378
PCT Number:	US2017060964
Application Number:	62419743
Application Number:	62525057
PCT Number:	US2017060963

PATENT

Property Type	Number
Application Number:	62672950
PCT Number:	US2019032498
Application Number:	62782943
Application Number:	16721872
PCT Number:	US2019067513
Application Number:	13951284
Application Number:	14133350
Application Number:	15465406
PCT Number:	FR2001000602
Application Number:	09798452
PCT Number:	FR2005002489
Application Number:	12194644
Application Number:	12635965
PCT Number:	FR2008001728
Application Number:	12814994
Application Number:	14377126

#### CORRESPONDENCE DATA

Fax Number: (202)662-6291

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 2026626000

Email: greed@cov.com

Correspondent Name: COVINGTON & BURLING LLP

Address Line 1: ONE CITYCENTER, 850 TENTH STREET, NW

Address Line 2: ATTN: PATENT DOCKETING

Address Line 4: WASHINGTON, D.C. 20001

ATTORNEY DOCKET NUMBER:	036617.00048
NAME OF SUBMITTER:	GENEE REED
SIGNATURE:	/Genee Reed/
DATE SIGNED:	03/09/2023

#### Total Attachments: 10

source=Project Rainbow - Termination and Release of Patent Security Agreement Executed#page1.tif  
source=Project Rainbow - Termination and Release of Patent Security Agreement Executed#page2.tif  
source=Project Rainbow - Termination and Release of Patent Security Agreement Executed#page3.tif  
source=Project Rainbow - Termination and Release of Patent Security Agreement Executed#page4.tif  
source=Project Rainbow - Termination and Release of Patent Security Agreement Executed#page5.tif  
source=Project Rainbow - Termination and Release of Patent Security Agreement Executed#page6.tif  
source=Project Rainbow - Termination and Release of Patent Security Agreement Executed#page7.tif  
source=Project Rainbow - Termination and Release of Patent Security Agreement Executed#page8.tif  
source=Project Rainbow - Termination and Release of Patent Security Agreement Executed#page9.tif



**TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT**

This **TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT** (this “**Termination and Release**”) is granted as of March 2, 2023, by **PONTIFAX MEDISON FINANCE GP, L.P.**, as collateral agent and administrative agent (“**Agent**”) in favor of **OPIANT PHARMACEUTICALS, INC.**, a Delaware corporation (“**Grantor**”).

**WHEREAS**, the Grantor executed and delivered a Patent Security Agreement, dated as of December 10, 2020 (the “**Agreement**”), granting to the Agent a security interest in all of its right, title and interest, whether presently existing or hereafter acquired, in, to and under the Patents (as defined in the Agreement), notice of which was recorded with the United States Patent and Trademark Office (“**USPTO**”) on December 10, 2020 at Reel 054602, Frame 0192;

**WHEREAS**, Grantor has requested that Agent hereby terminate, release and discharge fully its security interests in and liens on all right, title and interest of Grantor in, to and under all of the Patents as herein provided; and

**WHEREAS**, Grantor has requested that the Agent provide a document suitable for recording with the USPTO to evidence the release of the Agent’s security interests in and liens on the Patents as herein provided.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby:

1. terminates the Agreement and releases, terminates and discharges fully all liens and security interests thereunder in Grantor’s right, title and interest in, to and under the Patents, including, without limitation, those patents and patent applications identified in Schedule I hereto; and
2. authorizes and requests that this Termination and Release be recorded with the USPTO.

[Signature page follows]

**IN WITNESS WHEREOF**, the undersigned has executed this Termination and Release by its duly authorized officer as of the date first above written.

**PONTIFAX MEDISON FINANCE GP, L.P.**  
as Agent

By: \_\_\_\_\_  
Name: Momi Karako  
Title: Partner

SCHEDULE I  
TO  
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT

Patents

(see attached 7 pages)

## 1. Owned or Co-Owned Patents

Case Number	Title	Inventors	App. No.	Filing Date	Publ. No.	Publ. Date	Patent Number	Issue Date	App. Status	Exp. Date	Owner Name
OPI0109-101-US	METHODS, PARENTERAL PHARMACEUTICAL FORMULATIONS, AND DEVICES FOR THE PREVENTION OF OPIOID OVERDOSE	Roger Crystal, Phil Skolnick	62/756,903	11/7/2018	-	-	-	-	Expired	11/7/2019	Opiant Pharmaceuticals
OPI0109-401-PC	METHODS, PARENTERAL PHARMACEUTICAL FORMULATIONS, AND DEVICES FOR THE PREVENTION OF OPIOID OVERDOSE	Roger Crystal, Phil Skolnick	PCT/US2019/060185	11/7/2019	WO2020097279	5/14/2020			Pending	11/7/2039	Opiant Pharmaceuticals
OPI0111-101-US	COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST	Phil Skolnick	62/776,888	12/7/2018					Pending	12/7/2019	Opiant Pharmaceuticals
OPI0111-102-US	COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST	Phil Skolnick	62/862,832	6/18/2019					Pending	6/18/2020	Opiant Pharmaceuticals
OPI0111-201-US	COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST	Phil Skolnick	16/704,699	12/5/2019	2020-0179271	6/11/2020			Pending	12/5/2039	
OPI0111-401-PC	COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST	Phil Skolnick	PCT/US2019/064672	12/5/2019	WO2020118048	6/11/2020			Pending	12/5/2039	Opiant Pharmaceuticals
OPI0112-101-US	COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME WITH A CANNABINOID RECEPTOR ANTAGONIST	Phil Skolnick	62/862,830	6/18/2019					Pending	6/18/2020	Opiant Pharmaceuticals

OPI0112-201-US	COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME WITH A CANNABINOID RECEPTOR ANTAGONIST	Skolnick, Phil	16/904,359	6/17/2020					Pending	6/17/2040	Opiant Pharmaceuticals
OPI0112-401-PC	COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME WITH A CANNABINOID RECEPTOR ANTAGONIST	Skolnick, Phil	PCT/US2020/038215	6/17/2020					Pending	6/17/2040	Opiant Pharmaceuticals
OPI0116-101-US	COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST	Skolnick, Phil	63/037,351	6/10/2020					Pending	6/10/2021	Opiant Pharmaceuticals
OPI0116-201-US	COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST	Skolnick, Phil	16/904,403	6/17/2020					Pending	6/17/2040	Opiant Pharmaceuticals
OPI0116-401-PC	COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST	Skolnick, Phil	PCT/US2020/038211	6/17/2020					Pending	6/17/2040	Opiant Pharmaceuticals

## 2. Licensed Patents

Case Number	Title	Inventors	Application No.	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Expiration Date	Owner Name
OPI0101-101-US (AEGIS1470)	Compositions And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal	62/354,465	6/24/2016	n/a	n/a	n/a	n/a	Expired	6/24/2017	Opiant Pharmaceuticals
OPI0101-102-US (AEGIS1470)	Compositions And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal	62/419,736	11/9/2016	n/a	n/a	n/a	n/a	Expired	11/9/2017	Opiant Pharmaceuticals
OPI0101-101-PC (AEGIS1470/WO/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	PCT/US2017/039300	6/26/2017	WO 2017/223566	12/28/2017			MONITOR - Nat Phase	6/24/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-501-AU (AEGIS1470/AU/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	2017281941	6/26/2017					MONITOR - Pending	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)



Case Number	Title	Inventors	Application No.	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Expiration Date	Owner Name
OPI0101-502-CA (AEGIS147 0/CA/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	3,028,731	6/26/2017					MONITOR - Pending	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-503-CN (AEGIS147 0/CN/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	20178004405 7.3	6/26/2017	CN109789122 A	5/21/2019			MONITOR - Published	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-504-EP (AEGIS147 0/EP/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	17186377.0	6/26/2017	EP3474842	5/1/2019			MONITOR - Published	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-504-HK (AEGIS147 0/HK/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	19128321.7	6/26/2017					MONITOR - Pending	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-505-JP (AEGIS147 0/JP/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	2018-567665	6/26/2017					MONITOR - Pending	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-506-MX (AEGIS147 0/MX/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	MX/a/2018/0 15985	6/26/2017					MONITOR - Pending	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-507-NZ (AEGIS147 0/NZ/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	750067	6/26/2017					MONITOR - Pending	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-508-PH (AEGIS147 0/PH/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	N/A	6/26/2017					MONITOR - Pending	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-509-RU (AEGIS147 0/RU/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	2019101810	6/26/2017					MONITOR - Pending	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-510-SG (AEGIS147 0/SG/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	11201811580 S	6/26/2017					MONITOR - Pending	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-511-KR (AEGIS147 0/KR/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	10-2019-7001264	6/26/2017					MONITOR - Pending	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0101-512-US (AEGIS147 0/US/2)	Compositions, Devices, And Methods For The Treatment Of Alcohol Use Disorder	Roger Crystal, Arvind Agrawal, Edward Maggio	16/311,944	12/20/2018					MONITOR - Pending	6/26/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0105-101-US (AEGIS145 0)	Compositions And Methods For The Treatment Of Opioid Overdose	Roger Crystal	62/424,378	11/18/2016	-	-	-	-	Expired	11/18/2017	Opiant Pharmaceuticals

KL2 3204681.3

Case Number	Title	Inventors	Application No.	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Expiration Date	Owner Name
OPI0105-401-PC (AEGIS145 0/WO/1)	Compositions And Methods For The Treatment Of Opioid Overdose	Roger Crystal	PCT/US2017 /060964	11/9/2017	WO2018/0936 66	5/24/2018			Expired	6/18/2019	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0105-501-AU (AEGIS145 0/AU/1)	Compositions And Methods For The Treatment Of Opioid Overdose	Roger Crystal	2017360910	11/9/2017					MONITOR - Pending	11/9/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0105-502-CA (AEGIS145 0/CA/1)	Compositions And Methods For The Treatment Of Opioid Overdose	Roger Crystal	3,044,221	11/9/2017	3044221	5/24/2018			MONITOR - Pending	11/9/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0105-503-CN (AEGIS145 0/CN/1)	Compositions And Methods For The Treatment Of Opioid Overdose	Roger Crystal	20178008171 9.4	11/9/2017	CN 110139651 A	8/16/2019			MONITOR - Published	11/9/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0105-504-EP (AEGIS145 0/EP/1)	Compositions And Methods For The Treatment Of Opioid Overdose	Roger Crystal	17871739.3	11/9/2017	3541386	9/25/2019			MONITOR - Published	11/9/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0105-505-IL (AEGIS145 0/IL/1)	Compositions And Methods For The Treatment Of Opioid Overdose	Roger Crystal	266674	11/9/2017					MONITOR - Pending	11/9/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0105-506-JP (AEGIS145 0/JP/1)	Compositions And Methods For The Treatment Of Opioid Overdose	Roger Crystal	2019-526565	11/9/2017	2019-534315	11/28/2019			MONITOR - Pending	11/9/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0105-507-RU (AEGIS145 0/RU/1)	Compositions And Methods For The Treatment Of Opioid Overdose	Roger Crystal	2019118465	11/9/2017					MONITOR - Pending	11/9/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0105-508-US (AEGIS145 0/US/1)	Compositions And Methods For The Treatment Of Opioid Overdose	Roger Crystal	16/461,354	5/15/2019	2020-0060967	2/27/2020			MONITOR - Pending	11/9/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0106-101-US (AEGIS146 0)	Compositions And Methods For The Treatment Of Opioid Overdose and Opioid-Receptor-Mediated Conditions	Roger Crystal	62/419,743	11/9/2016	-	-	-	-	Expired	11/9/2017	Opiant Pharmaceuticals
OPI0106-102-US (AEGIS146 0)	Compositions, Devices, And Methods For The Treatment Of Opioid Overdose and Opioid-Receptor-Mediated Conditions	Roger Crystal	62/525,057	6/26/2017	-	-	-	-	Expired	6/26/2018	Opiant Pharmaceuticals
OPI0106-401-PC (AEGIS146 0/WO/2)	Compositions, Devices, And Methods For The Treatment Of Opioid Overdose and Opioid-Receptor-Mediated Conditions	Roger Crystal	PCT/US2017 /060963	11/9/2017	WO 2018089709	5/17/2018			MONITOR - Nat Phase	11/9/2017	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0106-501-CA (AEGIS146 0/CA/2)	Compositions, Devices, And Methods For The Treatment Of Opioid-Receptor-Mediated Conditions	Roger Crystal	3,043,028	11/9/2017					MONITOR - Pending	11/9/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0106-502-EP (AEGIS146 0/EP/2)	Compositions, Devices, And Methods For The Treatment Of Opioid-Receptor-Mediated Conditions	Roger Crystal	17868907.1	11/9/2017	EP3538189	9/18/2019			MONITOR - Published	11/9/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0106-503-US (AEGIS146 0/US/2)	Compositions, Devices, And Methods For The Treatment Of Opioid-Receptor-Mediated Conditions	Roger Crystal	16/348,031	5/7/2019	US-2019-0262263-A1	8/29/2019			MONITOR - Published	11/9/2037	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0108-101-US (AEGIS149 0)	Formulations And Methods For The Prevention Of Opioid Overdose	Roger Crystal	62/672,950	5/17/2018	-	-	-	-	Expired	5/17/2019	Opiant Pharmaceuticals

Case Number	Title	Inventors	Application No.	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Expiration Date	Owner Name
OPI0108-401-PC (AEGIS149 0/WO/1)	Formulations And Methods For The Prevention Of Opioid Overdose	Roger Crystal	PCT/US2019 /32498	5/15/2019	WO 2019/222408	11/21/2019			MONITOR - Pending	5/15/2039	Aegis Therapeutics, LLC (excl. lic. to Opiant)
OPI0110-101-US (AEGIS148 0)	Compositions, Devices, And Methods For The Treatment Of Overdose And Reward-Based Disorders	Roger Crystal, Arvind Agrawal, Edward Maggio	62/782,943	12/20/2018	-	-	-	-	MONITOR - Pending	12/20/2019	Aegis Therapeutics, LLC (Opiant Pharmaceuticals depending on claims)
OPI0110-201-US (AEGIS148 0)	COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OVERDOSE AND REWARD-BASED DISORDERS	CRYSTAL, Roger; ELLISON, Mark; MAGGIO, Edward T.	16/721,872	12/19/2019					MONITOR -Act	12/19/2039	Opiant Pharmaceuticals / Aegis Therapeutics, LLC
OPI0110-401-PC (AEGIS148 0)	COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OVERDOSE AND REWARD-BASED DISORDERS	MAGGIO, Edward T.; CRYSTAL, Roger; ELLISON, Mark; SKOLNICK, Phil	PCT/US2019 /067513	12/19/2019	WO 2020-132263	6/25/2020			MONITOR -Act		Aegis Therapeutics, LLC (excl. lic. to Opiant)
AEGIS121 0/EP/17	Compositions For Drug Administration	Edward T. Maggio	14872645.8	12/17/2014	EP3082817	10/26/2016	EP3082817		MONITOR - Issued	12/17/2034	Aegis Therapeutics, LLC (excl. lic. to Opiant)
AEGIS121 0/IN/D1	Absorption Enhancers for Drug Administration	Edward T. Maggio	7078/DELNP /2012	8/25/2004					Abandoned	5/23/2018	Aegis Therapeutics, LLC
AEGIS121 0/US/15	Compositions For Drug Administration	Edward T. Maggio	13/951,284	7/25/2013	US-2014-0162965-A1	6/12/2014			MONITOR - Abandoned	7/20/2017	Aegis Therapeutics, LLC
AEGIS121 0/US/17	Compositions For Drug Administration	Edward T. Maggio	14/133,350	12/18/2013	US-2014-0107145-A1	4/17/2014	9,895,444	2/20/2018	MONITOR - Issued	5/11/2025	Aegis Therapeutics, LLC
AEGIS121 0/US/20	Anti-Bacterial Compositions For Drug Administration	Edward T. Maggio	15/465,406	3/21/2017	US-2017-0189472-A1	7/6/2017			MONITOR - Abandoned	7/24/2018	Aegis Therapeutics, LLC
OPI0113-401-PC	Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation	Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers	PCT/FR2001 /000602	3/1/2001	WO200106463 4	9/7/2001	-	-	Expired	-	Aventis Pharma, S.A. (excl. lic. to Opiant)
OPI0113-201-US	Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation	Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers	09/798,452	2/2/2001	n/a	n/a	6,355,631	3/12/2002	MONITOR - Issued	3/2/2021	Sanofi Mature IP (excl. lic. to Opiant)

Case Number	Title	Inventors	Application No.	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Expiration Date	Owner Name
OPI0113-502-JP	Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation	Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers	JP2001563477	3/1/2003	JP2003525270A	8/26/2003	JP4883867	12/16/2011	MONITOR - Issued	3/1/2021	Sanofi Mature IP (excl. lic. to Opiant)
OPI0114-401-PC	Method and intermediates for the preparation of derivatives of N (1-benzhydrylazetid-3-yl)-N-phenylmethylsulfonamide	Philippe Boffelli, Michel Delthil, Luc Grondard, Maxime Lampilas, Joel Malpart, Stephane Mutti, Lahlou Nait-Bouda, Joerg Reike-Zapp	PCT/FR2005/002489	10/10/2005	WO2006040464A1	4/20/2006	-	-	Expired	-	Sanofi-Aventis (excl. lic. to Opiant)
OPI0114-501-US	Method and intermediates for the preparation of derivatives of N (1-benzhydrylazetid-3-yl)-N-phenylmethylsulfonamide	Philippe Boffelli, Michel Delthil, Luc Grondard, Maxime Lampilas, Joel Malpart, Stephane Mutti, Lahlou Nait-Bouda, Joerg Reike-Zapp	12/194,644	8/20/2008	2008-0312205	12/18/2008	7,652,154	1/26/2010	MONITOR - Issued	10/10/2025	Sanofi (excl. lic. to Opiant)
OPI0114-501D1-US	Method and intermediates for the preparation of derivatives of N (1-benzhydrylazetid-3-yl)-N-phenylmethylsulfonamide	Philippe Boffelli, Michel Delthil, Luc Grondard, Maxime Lampilas, Joel Malpart, Stephane Mutti, Lahlou Nait-Bouda, Joerg Reike-Zapp	12/635,965	12/11/2009	2010-0087414	4/8/2010	8,071,788	12/6/2011	MONITOR - Issued	10/10/2025	Sanofi (excl. lic. to Opiant)

Case Number	Title	Inventors	Application No.	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Expiration Date	Owner Name
OPI0115-401-PC	Method for preparing azetidine derivatives	Antony Bigot, Philippe Boffelli, Maxime Lampilas, Pascale Marolleau, Alain MedardGilles-Oddon, Daniel Varraillon	PCT/FR2008/001728	12/12/2008	WO2009103883	8/27/2009	-	-	Expired	-	Sanofi-Aventis
OPI0115-501-US	Method for preparing azetidine derivatives	Antony Bigot, Philippe Boffelli, Maxime Lampilas, Pascale Marolleau, Alain MedardGilles-Oddon, Daniel Varraillon	12/814,994	6/14/2010	2011-0118481	5/19/2011	8,207,355	6/26/2012	MONITOR - Issued	12/12/2028	Sanofi
003/430/SAP	Induction of highly specific antibodies to a hapten but not to a carrier peptide by immunization	Carl R. Alving, Gary R. Matyas, Arthur E. Jacobson, Fuying Li, Malliga R. Iyer, Kenner C. Rice, Kejun Cheng, Alexander Mayorov	14/377,126	8/6/2014	US20150098935A1	4/9/2015	9193739	11/24/2015	MONITOR - Issued	8/6/2024	The Government Of The United States Of America As Represented By The Secretary Of The Army